Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| MLYS | PRESS-RELEASE | neutral | 2/10 | Mineralys Therapeutics granted inducement equity awards totaling 81,253 shares (46,430 stock options + 34,823 RSUs) to t | Sep 29, 2026 |
| LEGN | 144 | neutral | 2/10 | Director Corazon (Corsee) D. Sanders filed a Form 144 notice to sell 13,685 ADSs valued at approximately $258,915. The s | Sep 29, 2026 |
| ABVC | DEF 14A | bearish | 6/10 | ABVC BioPharma is holding a special meeting on October 28, 2026, to seek shareholder approval for three proposals: (1) a | Sep 29, 2026 |
| GMAB | 6-K | neutral | 2/10 | Genmab filed its updated Articles of Association as a 6-K, reflecting routine governance updates including share capital | Sep 29, 2026 |
| SLXN | 8-K | bearish | 7/10 | Silexion Therapeutics entered into an inducement letter with holders of 3,216,928 Series E warrants, who agreed to exerc | Sep 29, 2026 |
| ONCY | 8-K | neutral | 3/10 | Oncolytics Biotech announced a publication in the Proceedings of the National Academy of Sciences showing that its inves | Sep 29, 2026 |
| ARQT | PRESS-RELEASE | neutral | 3/10 | Arcutis Biotherapeutics announced a celebrity endorsement partnership with Simone Biles to launch the 'Skin to Believe I | Sep 29, 2026 |
| MBRX | 8-K | bullish | 6/10 | Moleculin Biotech announced it has completed and closed enrollment in Part A of its pivotal Phase 2/3 MIRACLE trial eval | Sep 29, 2026 |
| MBRX | PRESS-RELEASE | neutral | 6/10 | Moleculin announced completion of Part A enrollment in the pivotal Phase 2/3 MIRACLE trial of Annamycin for R/R AML, wit | Sep 29, 2026 |
| ARGX | 6-K | bullish | 6/10 | argenx presented a broad set of clinical data at the 2026 AANEM and MGFA meetings, including Phase 3 ADAPT OCULUS result | Sep 29, 2026 |
| ONMD | 8-K | neutral | 3/10 | OneMedNet Corp filed a Certificate of Amendment to effect a 1-for-10 reverse stock split, effective September 29, 2026, | Sep 29, 2026 |
| PPCB | PRESS-RELEASE | neutral | 4/10 | Propanc Biopharma reported a year-end net loss of $18.86M for FY2026, improved from a $58.92M loss in FY2025, with zero | Sep 29, 2026 |
| LITS | PRESS-RELEASE | neutral | 5/10 | Lite Strategy reported FY2026 results, its first full year operating under a Litecoin (LTC) treasury strategy. The compa | Sep 29, 2026 |
| NAMS | 8-K | neutral | 4/10 | NewAmsterdam Pharma announced the dosing of the first patient in SPINOZA, a Phase 2b trial evaluating obicetrapib in ~40 | Sep 29, 2026 |
| VOR | PRESS-RELEASE | bullish | 6/10 | Vor Bio announced positive post hoc Phase 3 data for telitacicept in generalized myasthenia gravis, showing >94% of part | Sep 29, 2026 |
| SLXN | PRESS-RELEASE | bearish | 6/10 | Silexion Therapeutics entered into definitive agreements for the immediate cash exercise of outstanding Series E warrant | Sep 29, 2026 |
| KROS | 8-K | bullish | 6/10 | Keros Therapeutics announced a $20 million development milestone payment from partner Takeda triggered by first patient | Sep 29, 2026 |
| IMNN | 8-K | bearish | 5/10 | Imunon (IMNN) exchanged $1.2M of its secured promissory A-1 Note held by Streeterville Capital for 120 shares of newly c | Sep 29, 2026 |
| ALLR | 8-K | neutral | 2/10 | Allarity Therapeutics announced the expansion of its in-house medical laboratory to include proteomics and cell line res | Sep 29, 2026 |
| ATOS | 8-K | neutral | 4/10 | Atossa Therapeutics announced a plan to issue one contingent value right (CVR) per share of common stock, entitling hold | Sep 29, 2026 |
| UNCY | 8-K | bullish | 7/10 | Unicycive Therapeutics resubmitted its NDA for oxylanthanum carbonate (OLC) to the FDA on September 29, 2026, using a ne | Sep 29, 2026 |
| RNAC | 8-K | bullish | 6/10 | Cartesian Therapeutics announced additional positive retreatment data for its lead CAR-T candidate, Descartes-08, in mya | Sep 29, 2026 |
| ELAB | PRESS-RELEASE | neutral | 3/10 | PMGC Holdings subsidiary NorthStrive Biosciences engaged Charles River Laboratories for analytical characterization work | Sep 29, 2026 |
| OPTH | 6-K | neutral | 2/10 | Optimi Health Corp. announced the appointment of Melanie Pump to its Board of Directors and the resignation of Leah Hodg | Sep 29, 2026 |
| IVVD | 8-K | bullish | 7/10 | Invivyd announced positive topline results from the LIBERTY Phase 3 study, showing VYD2311 met all primary and secondary | Sep 29, 2026 |
| IMMX | 424B5 | bearish | 6/10 | Immix Biopharma is offering 11,363,637 shares of common stock at $11.00 per share via an underwritten public offering le | Sep 29, 2026 |
| AQST | 8-K | neutral | 2/10 | Aquestive Therapeutics appointed Richard J. Daly to its Board of Directors, effective October 14, 2026, expanding the bo | Sep 29, 2026 |
| IOVA | 8-K | bullish | 6/10 | Iovance Biotherapeutics raised its full year 2026 total revenue guidance to $410–$420 million, up from the prior range o | Sep 29, 2026 |
| ALT | 8-K | neutral | 2/10 | Altimmune appointed Richard Menziuso as Vice President, Global Controller and Principal Accounting Officer, effective Se | Sep 29, 2026 |
| BYSI | 8-K | mixed | 6/10 | BeyondSpring entered into a definitive agreement to sell its wholly owned subsidiary (which indirectly holds a 57.97% st | Sep 29, 2026 |